TITLE

A Prospective Study of Fasting Plasma Glucose and Risk of Stroke in Asymptomatic Men

AUTHOR(S)
XUEMEI SUI; LAVIE, CARL J.; HOOKER, STEVEN P.; DUCK-CHUL LEE; COLABIANCHI, NATALIE; CHONG-DO LEE; BLAIR, STEVEN N.
PUB. DATE
November 2011
SOURCE
Mayo Clinic Proceedings;Nov2011, Vol. 86 Issue 11, p1042
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: To examine the association between levels of fasting plasma glucose (FPG) and incidence of stroke outcomes in a large cohort of asymptomatic men. PATIENTS AND METHODS: Participants were 43,933 men (mean ± SD age, 44.3±9.9 years) who were free of known cardiovascular disease at baseline and whose FPG levels were assessed during a preventive medical examination at the Cooper Clinic, Dallas, TX, between January 7, 1971, and March 11, 2002. Patients with diagnosed diabetes mellitus (DM) or low FPG (<80 mg/dL [to convert to mmol/L, multiply by 0.0555]) were excluded. Fatal stroke was identified through the National Death Index, and nonfatal stroke was ascertained from mail-back surveys. RESULTS: A total of 595 stroke events (156 fatal and 456 nonfatal strokes; 17 men reported a nonfatal stroke before they died of stroke) occurred during 702,928 person-years of exposure. Age-adjusted fatal, nonfatal, and total stroke event rates per 10,000 person-years for normal FPG (80-109 mg/dL), impaired fasting glucose (110-125 mg/dL), and undiagnosed DM (≥126 mg/dL) were 2.1, 3.4, and 4.0 (Ptrend=.002); 10.3, 11.8, and 18.0 (Ptrend=.008); and 8.2, 9.6, and 12.4 (Ptrend=.008), respectively. After further adjusting for potential confounders, the direct association between FPG and fatal, nonfatal, or total stroke events remained significant (Ptrend=.02, .03, and .01, respectively). For FPG levels of 110 mg/dL or greater, each 10-unit increment of FPG was associated with a 6% higher risk of total stroke events (P=.05). CONCLUSION: Hyperglycemia (FPG, ≥110 mg/dL), even below the DM threshold (such as with impaired fasting glucose), was associated with a higher risk of fatal, nonfatal, or total stroke events in asymptomatic men.
ACCESSION #
67320950

 

Related Articles

  • Evaluation of daily glycemic profiles in well controlled children with type 1 diabetes mellitus using a continuous glucose monitoring system. Tucholski, Krzysztof; Deja, Grażyna; Skała-Zamorowska, Eliza; Jarosz-Chobot, Przemysława // Pediatric Endocrinology, Diabetes & Metabolism;2009, Vol. 15 Issue 1, p29 

    Introduction: Effective diabetes mellitus management requires to maintain blood glucose levels in a narrow range between hyperglycemia causing late complications, and danger of severe hypoglycemia. This objective may be difficult to achieve especially in small children. The aim of the study:...

  • A Novel Methodology to Evaluate Continuous Glucose Monitoring Accuracy and Clinical Representation of Glucose Exposure and Variability. Mazze, Roger S.; Strock, Ellie; Stout, Philip; Racchini, Joel; Wesley, David; Borgman, Sarah // Diabetes;Jun2007 Supplement 1, Vol. 56, pA107 

    SMBG combined with Ambulatory Glucose Profile (AGP) analysis was used to determine whether time lag and difference between glucose in blood and interstitial fluid (ISF) could be ameliorated. For 8 days subjects with type 1 diabetes used Guardian RT® (RT) for CGM and OneTouch Ultra® (OT)...

  • Model Based Simulation for Type I Diabetic Patients. Kamath, Surekha // Journal of Control Engineering & Technology;Jan2014, Vol. 4 Issue 1, p17 

    Maintaining the glucose level in normoglycaemic range is challenging in Type I diabetic patients. An attempt has been made in this paper to derive a control strategy for blood glucose regulation. Due to cost and complexity involved in testing the control algorithms to real patients, studies are...

  • 1,5-Anhydroglucitol and Postprandial Hyperglycemia as Measured by Continuous Glucose Monitoring System in Moderately Controlled Patients With Diabetes. Dungan, Kathleen M.; Buse, John B.; Largay, Joseph; Kelly, Mary M.; Button, Eric A.; Kato, Shuhei; Wittlin, Steven // Diabetes Care;Jun2006, Vol. 29 Issue 6, p1214 

    OBJECTIVE -- Postprandial hyperglycemia is often inadequately assessed in diabetes management. Serum 1,5-anhydroglucitol (1,5-AG) drops as serum glucose rises above the renal threshold for glucose and has been proposed as a marker for postprandial hyperglycemia. The objective of this study is to...

  • Real-Time Improvement of Continuous Glucose Monitoring Accuracy. FACCHINETTI, ANDREA; SPARACINO, GIOVANNI; GUERRA, STEFANIA; LUIJF, YOERI M.; DEVRIES, J. HANS; MADER, JULIA K.; ELLMERER, MARTIN; BENESCH, CARSTEN; HEINEMANN, LUTZ; BRUTTOMESSO, DANIELA; AVOGARO, ANGELO; COBELLI, CLAUDIO // Diabetes Care;Apr20123, Vol. 36 Issue 4, p793 

    OBJECTIVE--Reliability of continuous glucose monitoring (CGM) sensors is key in several applications. In this work we demonstrate that real-time algorithms can render CGM sensors smarter by reducing their uncertainty and inaccuracy and improving their ability to alert for hypo- and hyperglycemic...

  • Undiagnosed diabetes: Does it matter? Young, T. Kue; Mustard, Cameron A. // CMAJ: Canadian Medical Association Journal;1/09/2001, Vol. 164 Issue 1, p24 

    Background: The 1998 Canadian clinical practice guidelines for the management of diabetes lowered the cutoff point for diagnosing diabetes mellitus from a fasting plasma glucose (FPG) level of 7.8 to 7.0 mmol/L. We studied the prevalence and clinical outcomes of undiagnosed and diagnosed...

  • Problems Associated With Subcutaneously Implanted Glucose Sensors. Gerritsen, Martijn // Diabetes Care;Feb2000, Vol. 23 Issue 2, p143 

    Editorial. Highlights issues associated with the application of implantable glucose sensor for glucose level monitoring in diabetics. In vitro performance of the sensors; Evaluation on the accuracy of the implanted sensors; Importance of sufficient blood supply for sensor performance.

  • FDA Approves New Blood Glucose Device. Preboth, Monica // American Family Physician;9/1/2000, Vol. 62 Issue 5, p1195 

    Reports on the approval of a blood glucose monitor called FreeStyle that allows patients with diabetes to obtain blood samples from places other than fingertips by the United States Food and Drug Administration. Description of FreeStyle and how it is used; How the device may improve the...

  • Use of the Continuous Glucose Monitoring System to Guide Therapy in Patients With Insulin-Treated Diabetes: A Randomized Controlled Trial. Tanenberg, Robert; Bode, Bruce; Lane, Wendy; Levetan, Claresa; Mestman, Jorge; Harmel, Anne Peters; Tobian, Janet; Gross, Todd; Mastrototaro, John // Mayo Clinic Proceedings;Dec2004, Vol. 79 Issue 12, p1521 

    OBJECTIVE: To show improved glycemic control in patients with insulin-treated diabetes after adjustments to the diabetes management plan based on either continuous glucose monitoring using the Continuous Glucose Monitoring System (CGMS) or frequent self-monitoring of blood glucose (SMBG) using a...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics